London, 18 March 2015: Technavio, the independent tech-focused global research firm, has published a report on the Global Small Cell Lung Cancer Therapeutics Market 2015-2019, which is expected to grow at a slow pace and post a CAGR of 3.6 percent during the period 2014-2019.
“The Lung Cancer Alliance in the US is involved in conducting campaigns to create public awareness about lung cancer,” says Faisal Ghaus, Vice President of TechNavio.
“It provides support to patients in terms of access to medicines and reimbursement for testing and diagnosis of the disease.”
Key Market Drivers
- High Unmet Needs
- Rise in Disease Prevalence
- Promising Drug Pipeline
- Increase in Risk Factors
- Increase in Environmental Pollution
Key Market Trends
- Strategic Alliances
- Increase in Public Awareness
- Growing Focus on Emerging Markets
Key Market Vendors
- Bristol-Myers Squibb Co.
- GlaxoSmithKline plc
- Menarini Group
- Sanofi SA
- ZIOPHARM Oncology Inc.
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
